key: cord-0930080-vkouhd65
authors: Abugattas Nunez del Prado, J.; Quintana Reyes, A.; Blume La Torre, J.; Gutierrez Loli, R.; Pinzon Olejua, A.; Chamorro Chirinos, E.; Loza Mauricio, F. A.; Maguina, J. L.; Leon, J.; Rodriguez-Aliaga, P.; Mampaacutelaga-Trillo, E.
title: Clinical validation of RCSMS: a rapid and sensitive CRISPR-Cas12a test for the molecular detection of SARS-CoV-2 from saliva
date: 2021-04-27
journal: nan
DOI: 10.1101/2021.04.26.21256081
sha: 77a531ca280a3e7fdda093aaac10384656fb5800
doc_id: 930080
cord_uid: vkouhd65

Early detection of SARS-CoV-2 using molecular techniques is paramount to the fight against COVID-19. Due to its high sensitivity and specificity, RT-qPCR is the 'gold standard' method for this purpose. However, its technical requirements, processing time and elevated costs hamper its use towards massive and timely molecular testing for COVID-19 in rural and socioeconomically deprived areas of Latin America. The advent and rapid evolution of CRISPR-Cas technology has boosted the development of new pathogen detection methodologies. Recently, DETECTR -a combination of isothermal RT-LAMP amplification and Cas12a-mediated enzymatic detection- has been successfully validated in the Netherlands and the USA as a rapid and low-cost alternative to RT-qPCR for the detection of SARS-CoV-2 from nasopharyngeal swabs. Here, we evaluated the performance of RCSMS, a locally adapted variant of DETECTR, to ascertain the presence of SARS-CoV-2 in saliva samples from 276 patients in two hospitals in Lima, Peru (current status over a total of 350 samples). We show that a low-cost thermochemical treatment with TCEP/EDTA is sufficient to inactivate viral particles and cellular nucleases in saliva, eliminating the need to extract viral RNA with commercial kits, as well as the cumbersome nasopharyngeal swab procedure and the requirement of biosafety level 2 laboratories for molecular analyses. Our clinical validation shows that RCSMS detects up to 5 viral copies per reaction in 40 min, with sensitivity and specificity of 97.4% and 97.5% in the field, respectively, relative to RT-qPCR. Since CRISPR-Cas biosensors can be easily reprogrammed by using different guide RNA molecules, RCSMS has the potential to be quickly adapted for the detection of new SARS-CoV-2 variants. Furthermore, our field study validates use of lateral flow strips to easily visualize the presence of SARS-CoV-2, which opens up the possibility of deploying RCSMS as a 'point of care' test in environments with limited access to state-of-the-art diagnostic laboratories. In sum, RCSMS is a fast, efficient and inexpensive alternative to RT-qPCR for expanding COVID-19 testing capacity in low- and middle-income countries.

Given the rapid spread of the disease and the arrival of new pandemic waves, it remains urgent to implement early and massive SARS-CoV-2 testing strategies alongside with contact tracing and isolation (3) . Molecular tests must be sensitive, rapid and easily accessible to timely identify and treat individuals at high risk of transmitting the infection and efficiently apply partial lockdowns, border closures, and travel restrictions. In addition, molecular testing must be integrated into a genomic surveillance system that tracks the appearance and distribution of viral mutations. In sum, obtaining high-quality diagnostic data is essential to correctly monitor the evolution of the epidemic, ensure the success of public health strategies and the transition to a new normality.

Currently, ~600 COVID-19 diagnostic kits are commercially offered worldwide (4) . These tests are based on the detection of viral genes, viral proteins, or antibodies generated by the human immune system against the virus. While antibody tests are recommended for seroprevalence and epidemiological studies, the "gold standard" among COVID-19 molecular tests is the quantitative reverse transcription-polymerase chain reaction (RT-qPCR) (5) . Recently, viral antigen detection tests have added speed and accessibility to COVID-19 molecular testing, although their lower sensitivity relative to RT-qPCR limits their utility to individuals with high viral loads and risk of transmission (6) . In developing countries, RT-qPCR testing at the population level is restricted by poor access to adequate equipment, supplies and infrastructure, as well as by the need for trained personnel and high biosafety standards; in fact, most diagnostic kits in Latin America are produced in the developed world (7) . Hence, the local development and distribution of molecular detection methods are key to the fight against COVID-19 in these countries.

copies from viral RNA and amplify them exponentially at a single constant temperature (between 60 and 65°C), using three pairs of nested primers and a DNA polymerase with displacement and replication activities (9) , and ii) the second reaction exploits the CRISPR-Cas12a recognition system to target and detect the RT-LAMP-amplified viral gene sequence, unleashing the collateral DNAse activity of Cas12a and leading to the indiscriminate cut of single-stranded DNA reporter molecules that produce either fluorescent or immunochromatographic readouts upon cleavage (8) . A significant advantage of DETECTR over other methods is that it requires neither sophisticated equipment nor specialized personnel, and it is a low-cost alternative with sensitivity and specificity comparable to RT-qPCR (6) . Altogether, RT-LAMP and CRISPR-Cas12a reactions have a processing time of ~40 minutes, very convenient compared to the 2-4 hours required for the RT-qPCR reaction and its even longer data processing time (6) . Another important advantage of DETECTR over RT-qPCR is its ability to confirm the presence of SARS-CoV-2 RNA not only via standard fluorescence but also by using lateral flow strips, which simply requires replacing the fluorophore quencher with biotin in the reporter molecules. This results in an inexpensive visualization format, similar to a pregnancy test, easy to apply and interpret (8) . Importantly, various molecular tests that similarly combine RT-LAMP and CRISPR-Cas have successfully been used to detect Zika, Dengue and HIV viruses in humans, and some coronaviruses in animals (10) .

COVID-19 Nucleic Acid Tests (NATs) -such as DETECTR or RT-qPCR-have two major limitations related to sample collection. On one hand, the of nasopharyngeal swab procedure is uncomfortable for patients, risky for sample collection personnel, and generates the need for swabs and costly viral transport media. On the other hand, the extraction of high-quality viral RNA in standard laboratories requires commercial kits, expensive reagents and long processing times. Interestingly, recent studies have shown that respiratory samples can be directly lysed and used efficiently for molecular diagnostics without commercial RNA extraction kits (11) (12) (13) (14) . This simple incubation method uses standard low-cost laboratory equipment and is based on a simple thermochemical reaction that guarantees 1) inactivation of RNases in the sample and 2) lysis of viral particles, thus ensuring the release of viral genetic material and rendering the sample non-infectious (11) (12) (13) (14) . This is of great relevance for COVID-19 molecular testing in low and middle-income countries because it eliminates the need for highly trained personnel and biosafety level 2 facilities.

In the present study, we report the development, standardization and clinical validation of a new procedure that combines the efficiency and robustness of DETECTR (i.e. RT-LAMP and CRISPR-Cas coupled reactions) with the rapid and low-cost TCEP/EDTA thermochemical method for viral RNA preparation from saliva samples. We show that our integrated systemcalled Rapid Coronavirus-Sensitive Monitoring from Saliva, RCSMSsuccessfully detected SARS-CoV-2 RNA in a set of 276 saliva samples (current status from a total of 350 samples) from patients from two hospitals in Lima . The clinical diagnostic performance of RCSMS was   validated by comparison with routine RT-qPCR from nasopharyngeal swabs under field conditions. Together, our results show that RCSMS is a simple and easy-to-implement molecular test at the primary care level, outside the laboratory, with a great potential to contribute to the massification of COVID-19 molecular testing in Peru and neighboring countries.

The present study, aimed at validating the use of RCMS to test for the presence of SARS-CoV-2 in saliva from Peruvian patients, was developed in three stages: and d) the repeatability of measurements (three replicas). These evaluations also allowed us to optimize the efficiency, cost and readout levels of the test, as well as to verify its reproducibility upon variations in instrumentation and operators.

2) Analytical validation. To assess the analytical specificity of DETECTR, we relied on in vitro data from a similar study (8) and examined the possibility of cross-reactivity in the primers and guide RNAs used here. For this, we ran a comparative in silico analysis of the corresponding regions in common human coronavirus sequences (HCoV-HKU1 (NC_006577.2), HCoV-NL63 (NC_005831.2), HCoV-OC43 strain ATCC VR-759 (NC_006213.1), MERS-CoV (NC_019843.3), SARS-CoV (NC_004718) and SARS-CoV-2; NC_045512). The potential ability of the test to detect viral variants currently circulating in Perú was inferred by aligning . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Given the lack of information about the positivity rate in these hospitals, equal proportions (50%/50%) were assumed for the presence or absence of SARS-CoV-2 infection in these patients, as suggested by Macfarlane (16) . Regarding eligibility criteria, we selected ambulatory patients over 18 years of age who visited the hospital for SARS-CoV-2 detection having reported clinical symptomatology defined as: a) acute respiratory infection: cough and/or sore throat, general malaise, fever, headache, nasal congestion, shortness of breath, loss of smell, loss of taste, or b) severe acute respiratory infection: temperature ≥ 38°C and cough, with onset within the last 10 days. Subjects who had participated in vaccine clinical trials of vaccination programs against SARS-CoV-2 were excluded from the study, as were subjects with xerostomia, users of antiparkinsonian drugs, antipsychotics, and/or neuroleptics, and patients with more than three weeks of illness counted since the onset of symptoms.

Likewise, saliva samples of poor quality (containing blood, food residues or phlegm) and

volumes outside the optimal range (1-2 ml) were excluded. Upon being instructed about the study, the patients read and signed the informed consent. Nasopharyngeal swabs and saliva samples were collected following WHO recommendations, and molecularly analyzed in . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.26.21256081 doi: medRxiv preprint parallel (see below). For each participant, an absolute code was assigned to the data collection form and the samples, to protect their personal data and maintain the confidentiality of the results. Saliva samples were transferred the same day of the collection at 4°C to UPCH for RCSMS analysis of the E gene; nasopharyngeal swab samples remained at Guillermo Almenara Irigoyen National Hospital to be analyzed by RT-qPCR. Handling of the nasopharyngeal swabs and saliva samples was conducted under recommended biosafety standards for respiratory viruses. The analyses were run blind, so that the personnel in each laboratory ignored of test results of the other laboratory. Finally, we also evaluated the LOD of RCSMS by testing serial dilutions of synthetic RNA in a range of 5,000 to 1 viral copy per 10 µl RT-LAMP reaction, which included 2 µl of saliva inactivated with TCEP / EDTA and negative for SARS-CoV-2.

To select the ideal detection targets for this study as well as to establish their optimal amplification and detection parameters, we generated a panel of synthetic RNA templates encoding the viral genes N (934 bp), E (532 bp), S (540 bp), from Nsp6 to Nsp8 (734 bp), from Nsp10 to Nsp12 (798 bp) and the human POP7 gene (406 bp, sample quality control). These RNA templates were generated via in vitro transcription from PCR products modified to contain the sequence of the T7 transcriptional promoter at their 5 'end to allow their use in vitro transcription templates. The PCR reactions were performed using GoTaq G2 DNA polymerase (Promega) according to the conditions and cycling profile shown in Table 2 . After resolving the amplification products on 1% agarose gels, the corresponding bands were cut and purified with help of the GeneJet Gel DNA Extraction Kit (ThermoScientific). The DNA concentration in the eluates was quantified using a Nanodrop 2000 spectrophotometer (ThermoScientific) and 100 ng DNA were used for the in vitro transcription reaction using the AmpliScribe T7-Flash Transcription Kit (Lucigen), following the manufacturer's recommendations. The resulting RNA templates were purified with the GenElute kit (Sigma) and quantified with the Qubit 4.0 fluorometer using the RNA BR assay kit (Invitrogen). In addition, the integrity of the RNA was verified by denaturing agarose electrophoresis. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 27, 2021.

The sets of six primers for the LAMP amplification of each viral gene (Table 1) were previously conjugated in a 10X master mix (Table 3) . For the RT-LAMP reaction, a mixture of 0.2 µl Warmstart RTx Reverse Transcriptase and 0.5 µl Bst 3.0 DNA polymerase (NEB) were used, taking as input material 5 µl of purified RNA or 2 µl of inactivated saliva in a total volume of 10 µl (8 mM final concentration of MgSO4) and running the reactions for 30 min at 62°C. 

The RT-qPCR of viral genes Orf1ab and N run at UPCH used the in vitro diagnostic (IVD) FTD-SARS-CoV-2 kit (Siemens) and QTower 3G real-time thermocyclers (Analytik-Jena). The RT-qPCRs performed at the Guillermo Almenara Irigoyen National Hospital used the IVD Viasure SARS-CoV-2 Real Time PCR Detection Kit (CerTest Biotec), which also amplifies the viral genes Orf1ab and N and the Rotor-Gene real-time PCR cycler (Qiagen). Diagnostic Ct threshold were set as recommended by each kit and according to WHO guidelines.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.26.21256081 doi: medRxiv preprint

A descriptive analysis of the sociodemographic and clinical characteristics of the population was carried out. These included measures of central tendency and dispersion that were calculated for the quantitative variables, as well as absolute and relative frequencies for the categorical variables. Likewise, the level of concordance (Cohen's Kappa coefficient) between RT-qPCR and RCSMS was calculated for both analytical and clinical validations, as well as sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), the area under the curve (AUC), accuracy of RCSMS, and PPV/ NPV simulations assuming various prevalence scenarios. A stratified analysis by time was also included (greater than 7 and less than 7 days of illness). The estimates included 95% confidence intervals (95% CI) with an exact binomial method, and a p value <0.05 was considered significant. All analyses were performed with the Stata software version 16.0 (StataCorp, College Station, TX, USA).

For data visualization and graphs GraphPad Prism 7.00 was used (GraphPad Software, La Jolla California USA, www.graphpad.com).

Participants in the clinical validation stage were enrolled and sampled according to the ethics protocols approved by the INCOR EsSalud CEI (certificate 02/2021-CEI) and UPCH (SIDISI code 202099). All the participants read and signed informed consents prior to providing samples for this study.

Synthetic RNA fragments of the viral genes N (934 bp) and E (540 bp), and the human POP7 gene (406 bp), were selected and used as templates to optimize the conditions for RT-LAMP reactions ( Fig. 2A and B) . The RT and LAMP reactions were run simultaneously in a single tube, taking 10,000 copies of synthetic RNA fragments as starting material, and using reaction time and temperature gradients. Comparative evaluation of the reactions by real-time fluorescence and agarose gel electrophoresis revealed that optimal amplification of the three fragments occurred after 30 minutes at 62°C (Fig. 2C ).

The next step involved the detection of the amplified viral fragments using CRISPR-Cas technology. To this end, we used 2 µl of the RT-LAMP amplified products as substrate and 2 µl of RT-PCR products -generated from the same synthetic templates-as positive controls.

The minimum and optimal pre-incubation time for the formation of the RNP complex (i.e.

Cas12a + guide RNA) was 10 min but it could be extended up to 30 min. Once formed, RNPs . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. ;  could be stored for up to 48 hours at 4°C. The detection reactions for the E, N and POP7 genes worked optimally when run for 10 minutes at 37°C in the presence of 50 nM of RNP complex, formed by equimolar concentrations of Cas12a enzyme and RNA guides, regardless of the length of the latter. 8 bp reporter probes yielded optimal signals at 20 nM (fluorescent readout) and 500 nM (immunochromatography readout) ( Fig. 3 and Video 1) The minimum threshold of positivity of the fluorescence measurements was set at 20,000 Relative Fluorescence Units (UFR) after 10 min of reaction, and with a maximum of 100,000 UFR. On the other hand, the appearance of immunochromatographic signals on the lateral flow strips was consistently achieved after 2 min incubation of the strips in the reaction tubes. The limit of detection (LOD)

for both viral genes was determined using serial dilutions of the synthetic RNA templates, covering the range from 250 to 1 viral copy per 10 µl RT-LAMP reaction. Remarkably, our assay was able of detect down to 1 copy of both N and E genes in fluorescence and immunochromatographic readings ( Fig. 4A and B and Table 5 ), showing excellent concordance and reproducibility between both detection formats.

To rule out the possibility of cross-detecting other, related coronaviruses in the sample, we performed an in silico analysis of the RT-LAMP primers and guide RNAs used in this study, by aligning their nucleotide sequences with the corresponding regions in the viral E and N genes of different human coronaviruses (see Materials and Methods). The analysis did not show significant similarities, except for the F3 primer of the E gene, which is incapable of producing amplification by itself, thus excluding its cross-reactivity (see Discussion).

The appearance of SARS-CoV-2 variants worldwide makes it necessary to update all diagnostic and therapeutic methods based on the molecular recognition of viral genes and proteins. Therefore, we analyzed the 944 Peruvian genomes available in the Nextstrain and GISAID databases by March 31, 2021, and examined all nucleotide polymorphisms within the E and N genes, which are the targets of this study (see Materials and Methods). The analysis confirmed the high conservation of the viral genomes and the absence of mutational hot spots in the N and E genes corresponding to the binding sites of primers and guide RNA. However, we identified a few minor exceptions (see Table 6 ). For example, for the E gene, we identified two unique viral sequences containing each a CàT transition (singleton mutations) at different positions of the F3 primer-binding site. For the N gene, a singleton mutation was found at the guide RNA binding site, as well as four mutations at the primer B3 binding site. The first two, singletons, and the third one (found only in two viral sequences) are located at the 5 'end of the target region. The fourth mutation, close to the 3 'end of the target region, was found in 22

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. ;  sequences. None of these point mutations, however, disrupted the amplification efficiency of either E or N genes by RT-LAMP (see Discussion). Table 7 and Table 9 ). Finally, as a measure of performance, the Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) curve was calculated at 1.0 (95% CI: 1.0-1.0).

Next, we set out to validate the field performance of our RCSMS procedure, which combines the biosensing capabilities of DETECTR (RT-LAMP/CRISPR-Cas12a coupled reactions) with the rapid and low-cost preparation of viral RNA with the TCEP/EDTA thermochemical method.

The cohort reported here so far amounted to 276 individuals (current status from a total of 350 samples). Their distributions according to gender, age group, time of illness and symptoms are shown in Table 8 . Interestingly, we noticed a higher proportion of female participants (n=158, 57.2%) and young adults (n=207, 75%), with a mean age of 44.5 years and standard deviation . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Fig. 6 ).

Statistical analyses ( Table 7 and Table 9 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.26.21256081 doi: medRxiv preprint second week of disease. Finally, by using serial dilutions of synthetic RNA from 5,000 to 1 viral copy per 10 µl RT-LAMP reaction, we found the limit of detection for our method (either using fluorescence or immunochromatography) to be 5 viral copies per RT-LAMP reaction of 10 µl ( Fig. 4C and Table 5 ), which is in close agreement with the limits of detection reported for DETECTR (8) and RT-qPCR (11) (12) (13) .

Perú ranks consistently at the top among the countries most affected by COVID-19 worldwide. To this date, we are not aware of field validation reports for other saliva, CRISPR-Cas-based tests for SARS-CoV-2 detection. Although nasopharyngeal swabs are a standard procedure for the collection of respiratory virus samples (3), their use raises the cost of testing, causes discomfort to the patient and increases the probability of transmission to and among sample collection personnel. Therefore, saliva tests are a significant step towards making COVID-19 diagnostics a routine task. Importantly, RCSMS implementation does not require biosafety level 2 laboratories because the lysis and inactivation of viral particles occur immediately after saliva collection, turning samples non-infectious and keeping them safe from degradation by . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.26.21256081 doi: medRxiv preprint nucleases. Furthermore, sample stability is an important precondition for the development of high-quality, point-of-care tests.

LAMP is a simple, robust and low-cost DNA amplification method that can be visualized by absorbance, gel electrophoresis or colorimetric reactions (19, 20) . However, these readouts do not discriminate between specific products and those obtained from the artifactual amplification of complex or contaminated templates (21) . Because LAMP is a highly efficient reaction, diagnostic methods consisting only of this step need careful handling to prevent aerosol contamination. In our hands, this was achieved by setting up LAMP reactions in a designated work area, separate from all other steps of the RCSMS protocol, and keeping the reaction tubes closed until used in the detection reaction. Notably, the CRISPR-Cas12a system adds precision to the protocol because it produces a signal only when the viral sequence is specifically recognized and cut by the Cas12a enzyme. This reaction sets off the indiscriminate cut -also by Cas12a-of hundreds of reporter molecules, thus amplifying the original LAMP signal with high resolution and intensity (22) .

In order to physically recognize nucleic acids, Cas12a must be "guided" by an RNA molecule complementary to its target sequence. This guide RNA has a bipartite structure, with a "stem" that forms a complex with Cas12a and a leader that matches and binds the target DNA sequence, giving the system its specificity (23) (24) (25) (26) (27) . The optimal size and sequence of guide RNAs vary according to the type of Cas enzyme and the target sequence to be detected. For instance, for Cas9 -the first endonuclease developed for genome editing (23)-the guide stem is 80 bp long and the leader varies between 17-23 bp (24), whereas Cas12a requires a 20 bp stem and a 21-23 bp leader (25, 26) , and Cas13a -which recognizes RNA targets-uses a 36 bp stem and a 28 bp leader (27) . Therefore, the design of guide RNAs using bioinformatic tools is crucial for the diagnostic specificity of RCSMS and all other CRISPR-Cas-based biosensors.

The guide RNAs used here (41 bp) efficiently detected the viral sequences targeted by Broughton and colleagues in their DETECTR study with E and N genes (8) . Similar to what they report in their analytical validation, we observed more efficient and consistent detection of the E gene. This was particularly evident from the fluorescence signal levels (Fig. 5C ) and kinetics (Fig. 3) . Conversely, Brandsma et al. clinically validated the same system in three Dutch hospitals, but targeting only the N gene (17) . Interestingly, a clinical validation study by Patchsung et al. using a Cas13-based system found that the S gene (encoding the Spike protein) performed better than the Orf1ab and N genes (18) . We also attempted detection of the S gene but obtained only spurious and highly variable results (data not shown). This may be explained by the fact that their system used a different enzyme (Cas13a) and guide RNAs to detect different target sequences on a different type of nucleic acid (in vitro transcribed RNA, post-amplification). Given that the Spike protein mediates cellular entry of the virus, it is also relevant to consider the role of positive selection on the fixation of S gene mutations associated . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.26.21256081 doi: medRxiv preprint with infectivity and immunoevasion, as seen in the P.1 ("Brazilian"), B.1.351 ("South African"), B.1.1.7 ("British") variants (28) (29) (30) . For example, samples from a large number of UK COVID-19 patients were shown to have S genes that could not be amplified by RT-qPCR due to the ∆69/∆70 and N501Y mutations of B.1.1.7 (29, 30) . Interestingly, patients with this "S gene target failure" (SGTF) had a 55% higher risk of death than the original Wuhan strain (29, 30) , confirming that the B.1.1.7 is more transmissible and lethal than pre-existing SARS-CoV-2 variants. For diagnostic purposes, it is therefore advisable to target more conserved genetic sequences. Nonetheless, the versatility and specificity of DETECTR allow for rapid reprogramming of RCSMS (28) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. 100% in analytical validation) (8) and Brandsma et al (sensitivity 95.5% and specificity 92.9% in clinical validation) (17) , and for the Cas13 test by Zhang's group (sensitivity 96% and specificity 100% in clinical validation) (18) . Moreover, while we found seven incongruencies (18) . In these studies, the LOD from nasopharyngeal swabs reached 50 and 42 copies per 25 µl reaction (17, 18) . Notably, RCSMS routinely detected 50 copies per 10 µl reaction in triplicate assays, occasionally reaching five copies in one or two replicates.

Sensitivity and specificity are inherent properties of a test and therefore do not change between populations. However, the usefulness of a test, inferred from its predictive value, varies according to the true prevalence of the disease in a population. This is particularly relevant for COVID-19, where prevalence follows the evolution of complex geographical and temporal patterns of transmission, owing to demographic structure, human travel and migration. We estimated the predictive value of a test under different prevalence settings to determine adequate scenarios for its use. Generally, the NPV of diagnostic tests is expected to drop in high prevalence settings, as the number of false negatives increase (31). Nonetheless, our statistical simulation for RCSMS using the currently available data (276 out of 350 samples analyzed, Fig. 7) , predicts excellent NPVs >95% for prevalence scenarios as low as 1% and as high as 50%. Ensuring a low rate of false negatives (positive individuals being deemed negative) is especially desirable considering that COVID-19 is a serious, largely asymptomatic and contagious disease, for which early measures are advisable. Thus, a negative RCSMS result would maintain a very good level of accuracy in high prevalence settings (i.e. at a hospital with a high proportion of COVID-19 patients), even as the prevalence sinks due to the natural progression of the epidemic curve. Moreover, these data indicate that RCSMS could be used with confidence to rule out infection in low prevalence settings such as airports and land travel facilities, schools, universities, sporting or cultural events, as well as religious services and working environments with high flow of personnel, where ensuring negativity is important.

Our simulation also obtains adequate PPVs >95% and >90% for prevalence scenarios >20% and 10%, respectively. These PPV estimates are consistent with the results from our field study, where prevalence reached almost 30%, strengthening the conclusion that RCSMS is particularly well suited for the identification of positive cases during acute pandemic phases, such as the current second waves hitting Perú, India and Brazil. A sharp decrease of PPV in low prevalence settings is common to all diagnostic tests because of the higher probability of obtaining false positives (31). Notably, according to our simulation, RCSMS is expected to perform reasonably well (PPV>85%) even at a 5% prevalence scenario. As the pandemic . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.26.21256081 doi: medRxiv preprint recedes and the COVID-19 prevalence in the population decreases below 5%, it will be advisable to complement positive results using other molecular tests as well as diagnostic criteria (symptoms, oxygen saturation, chest X-ray/CT scan). Altogether, our data strongly suggest that RCSMS is sensitive enough to avoid missing infected individuals in high prevalence settings, and specific enough to maintain a very low proportion of erroneously diagnosed cases in low prevalence settings.

In conclusion, the present study integrates two methodologies that had been separately applied to COVID-19 testing: 1) the use of inactivated saliva as starting material for viral gene amplification (32) and 2) the use of DETECTR as a SARS-CoV-2 biosensor (8) . The resulting molecular test, RCSMS, can be easily implemented at the primary care level and diagnostic laboratories alike, using a simple lateral flow readout. To our knowledge, this is the first clinical validation of a CRISPR-Cas-based test for COVID-19 in Latin America using saliva, and one of the few of its type developed worldwide (33, 34, 35) . Noteworthy, an Argentinian group recently reported a DETECTR system (36) that uses nasopharyngeal swabs and fluorescence readouts. Within this group of newly validated CRISPR-Cas-based tests for the detection of SARS-CoV-2, RCSMS has the potential of becoming an important tool for the massification of COVID-19 molecular tests in Peru and neighboring countries. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. of an automated plate reader. Signals obtained at every time point were normalized against the background signal detected at t=o; the curves represent the change in normalized fluorescence units (I-I0, y axis) over time (min, x axis). In the example shown, the red, green and yellow curves correspond to 30 min data collection for N, E and P genes, respectively.

During such extended measurements, the E gene signal reached the instrument's top detection limit after 15 min, whereas the N and P gene signals continued to grow at a lower rate. test, comparing all groups against the group of "true negatives" as a control group. Note that the fold change in fluorescence is significantly greater for the viral gene E compared to N.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. ; PPV (blue line) and NPV (red line). In a scenario of >15% prevalence, both PPV and NPV >95%, whereas above 5% prevalence, the PPV >85%.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) For reference on reading the lateral flow strips, see Figure 1 .

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.26.21256081 doi: medRxiv preprint Table 5 : Limit of Detection (LOD) assay for analytical and clinical validation. RT-LAMP reactions of 10 µl carried out in triplicate with synthetic RNA of the viral genes E and N, were used as substrate for CRISPR-Cas12a detection. Up to 1 viral copy per reaction was detected in both genes during analytical validation and up to 5 viral copies per reaction (including 2 µl of SARS-CoV-2 negative inactivated saliva) during clinical validation. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.26.21256081 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 27, 2021 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.26.21256081 doi: medRxiv preprint Table 9 : Results of analytical and clinical (field) evaluations using the RT-qPCR and RT-LAMP / CRISPR-Cas tests. The degree of concordance is shown using the Kappa-Cohen index considering a 95% confidence interval (95% CI). . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.26.21256081 doi: medRxiv preprint

Ministerio de Salud del Perú. Sala situacional al 30 de Marzo 2021

Sistema Informatico nacional de Defunciones. Tablero de Control al 30 de Marzo 2021

Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. Interim guidance

Reflexiones de SEIMC sobre el uso de la detección de antígenos y anticuerpos para diagnóstico de COVID-19. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica

Advice on the use of point-of-care immunodiagnostic tests for COVID-19. WHO Scientific Brief

Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays

Diagnosing COVID-19: The Disease and Tools for Detection

CRISPR-Cas12-based detection of SARS-CoV-2

Loop-mediated isothermal amplification of DNA

Detection of RNA viruses from influenza and HIV to Ebola and SARS-CoV-2: a review

One-step RNA extraction for RT-qPCR detection of 2019-nCoV

A simple RNA preparation method for SARS-CoV-2 detection by RT-qPCR

Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality

Detection of severe acute respiratory syndrome coronavirus 2 and influenza viruses based on CRISPR-Cas12a

Conducting a Descriptive Survey: 2. Choosing a Sampling Strategy

Rapid, Sensitive, and Specific Severe Acute Respiratory Syndrome Coronavirus 2 Detection: A Multicenter Comparison Between Standard Quantitative Reverse-Transcriptase Polymerase Chain Reaction and CRISPR-Based DETECTR

Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA

A colorimetric RT-LAMP assay and LAMPsequencing for detecting SARS-CoV-2 RNA in clinical samples

Colorimetric Reverse TRANSCRIPTION Loop-Mediated ISOTHERMAL Amplification (RT-LAMP) as a VISUAL Diagnostic Platform for the Detection of the Emerging CORONAVIRUS SARS-COV-2

Loop-mediated isothermal amplification (LAMP) -review and classification of methods for sequence-specific detection

CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity

Development and applications of CRISPR-Cas9 for genome engineering

High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity

CRISPR Cpf1 proteins: structure, function and implications for genome editing

CRISPR-Cas12a: Functional overview and applications

RNA targeting with CRISPR-Cas13

Center of Disease Control and Prevention (CDC): Science Brief: Emerging SARS-CoV-2 Variants

CMMID COVID-19 Working Group. et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Investigation of Novel SARS-COV-2 Variant: Variant of Concern 202012/01

A smartphoneread ultrasensitive and quantitative saliva test for COVID-19

A Saliva-Based RNA Extraction-Free Workflow Integrated With Cas13a for SARS-CoV-2 Detection

An engineered CRISPR-Cas12a variant and DNA-RNA hybrid guides enable robust and rapid COVID-19 testing

Cas12a gRNA for SARS-CoV-2 N gene C12a-gRNA-E UAAUUUCUACUAAGUGUAGAUGUGGUAUUCUUGCUAGUUAC CRISPR-Cas12a gRNA for SARS-CoV-2 E gene

C12a-gRNA-P UAAUUUCUACUAAGUGUAGAUAAUUACUUGGGUGUGACCCU CRISPR-Cas12a gRNA for Human RNAse POP7 gene

We are profoundly indebted to: C.M. Caro, A. Rozas, J. Arriola, H. Añaños, J.C., F. León-Velarde, A. Sobarzo and especially M. and E. Arias for their generous support to this project, from the search for funding sources to assistance with the resolution of regulatory and

RT-LAMP for SARS-CoV-2 N gene